The selection of Purple Biotech's study for a late-breaking abstract poster presentation at a prestigious conference like ASCO suggests positive developments in its research. This could lead to increased investor interest and potentially positive movement in the stock price in the short term, as it reflects progress in the company's pipeline and potential for future revenue growth.